Fox Chase Cancer Center
2020 ASCO Update on Advanced RCC: Pembrolizumab + Axitinib vs. Sunitinib - Which Drug Showed Greater Response in the 1st Line Advanced Disease? Did MK-6482 Show Clinical Activity in Clear Cell Disease?
By
Fox Chase Cancer Center
FEATURING
Elizabeth R. Plimack
By
Fox Chase Cancer Center
FEATURING
Elizabeth R. Plimack
Login to view comments.
Click here to Login